arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Tonix Pharmaceuticals Holding Corp.

TNXP
$10.28 ▼ -0.33 (-3.16%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tonix Pharmaceuticals Holding Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $171.0M
Dividend Yield
Revenue Growth 577.9%
Op. Margin -314.1%
ROIC -15.1%
FCF / Share $-2.57
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.54M
↑ +577.9%
Net Income Profit after all expenses
$-40.19M
↓ -138.8%
FCF / Share Free cash flow per share
$-2.57
↑ +19.8%
Long-Term Debt Long-term obligations
$8.65M
↓ -7.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Financial Health
4
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 69 quarters